GW Pharmaceuticals (NASDAQ:GWPH) recently announced provisional results for 2020. These showed better than expected numbers and indicated a promising outlook going forward. However as I detailed in my article in November, the stock price continues to perform out of line with revenue announcements.
At that time the stock price had dropped after excellent Q3 results and something similar has happened this time. This seems to be mainly due to stock price manipulation and the share structure. Long-term the stock is a strong Buy on price dips.
2019 Full Year Provisional Results
As per